JP7129973B2 - ブロモドメイン阻害剤 - Google Patents
ブロモドメイン阻害剤 Download PDFInfo
- Publication number
- JP7129973B2 JP7129973B2 JP2019521064A JP2019521064A JP7129973B2 JP 7129973 B2 JP7129973 B2 JP 7129973B2 JP 2019521064 A JP2019521064 A JP 2019521064A JP 2019521064 A JP2019521064 A JP 2019521064A JP 7129973 B2 JP7129973 B2 JP 7129973B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- cancer
- methylisoquinolin
- methylsulfonylphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022066855A JP2022095897A (ja) | 2016-10-20 | 2022-04-14 | ブロモドメイン阻害剤 |
JP2024021416A JP2024056905A (ja) | 2016-10-20 | 2024-02-15 | ブロモドメイン阻害剤 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662410756P | 2016-10-20 | 2016-10-20 | |
US62/410,756 | 2016-10-20 | ||
PCT/US2017/057439 WO2018075796A1 (en) | 2016-10-20 | 2017-10-19 | Bromodomain inhibitor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022066855A Division JP2022095897A (ja) | 2016-10-20 | 2022-04-14 | ブロモドメイン阻害剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019535671A JP2019535671A (ja) | 2019-12-12 |
JP2019535671A5 JP2019535671A5 (zh) | 2020-10-22 |
JP7129973B2 true JP7129973B2 (ja) | 2022-09-02 |
Family
ID=62019669
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019521064A Active JP7129973B2 (ja) | 2016-10-20 | 2017-10-19 | ブロモドメイン阻害剤 |
JP2022066855A Pending JP2022095897A (ja) | 2016-10-20 | 2022-04-14 | ブロモドメイン阻害剤 |
JP2024021416A Pending JP2024056905A (ja) | 2016-10-20 | 2024-02-15 | ブロモドメイン阻害剤 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022066855A Pending JP2022095897A (ja) | 2016-10-20 | 2022-04-14 | ブロモドメイン阻害剤 |
JP2024021416A Pending JP2024056905A (ja) | 2016-10-20 | 2024-02-15 | ブロモドメイン阻害剤 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3528810A4 (zh) |
JP (3) | JP7129973B2 (zh) |
CN (1) | CN110099685A (zh) |
AR (1) | AR109859A1 (zh) |
AU (1) | AU2017345468B2 (zh) |
TW (1) | TW201821062A (zh) |
WO (1) | WO2018075796A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
TW201642860A (zh) * | 2015-04-22 | 2016-12-16 | 塞爾基因定量細胞研究公司 | 布羅莫結構域抑制劑 |
BR112021001019A2 (pt) * | 2018-07-23 | 2021-04-13 | Celgene Quanticel Research, Inc. | Processo para a preparação de inibidor de bromodomínio |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015058160A1 (en) | 2013-10-18 | 2015-04-23 | Quanticel Pharmaceuticals, Inc. | Bromodomain inhibitors |
WO2015078929A1 (en) | 2013-11-27 | 2015-06-04 | Oncoethix Sa | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds |
JP2016529246A (ja) | 2013-08-06 | 2016-09-23 | オンコエシックス ゲーエムベーハー | Betブロモドメイン阻害剤を用いるびまん性大細胞型b細胞性リンパ腫(dlbcl)の治療方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ20022332A3 (cs) * | 2000-01-07 | 2003-01-15 | Transform Pharmaceuticals, Inc. | Sestava vzorků |
GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
US9884806B2 (en) * | 2013-08-30 | 2018-02-06 | Icahn School Of Medicine At Mount Sinai | Cyclic vinylogous amides as bromodomain inhibitors |
TW201642860A (zh) * | 2015-04-22 | 2016-12-16 | 塞爾基因定量細胞研究公司 | 布羅莫結構域抑制劑 |
CN105732624B (zh) * | 2016-01-28 | 2019-08-02 | 中国药科大学 | 吡咯[4,3,2-de]喹啉-2(1H)-酮类BRD4蛋白抑制剂的制备方法及其用途 |
-
2017
- 2017-10-19 JP JP2019521064A patent/JP7129973B2/ja active Active
- 2017-10-19 CN CN201780076154.0A patent/CN110099685A/zh active Pending
- 2017-10-19 WO PCT/US2017/057439 patent/WO2018075796A1/en unknown
- 2017-10-19 EP EP17862619.8A patent/EP3528810A4/en active Pending
- 2017-10-19 AU AU2017345468A patent/AU2017345468B2/en active Active
- 2017-10-20 TW TW106136093A patent/TW201821062A/zh unknown
- 2017-10-20 AR ARP170102935A patent/AR109859A1/es unknown
-
2022
- 2022-04-14 JP JP2022066855A patent/JP2022095897A/ja active Pending
-
2024
- 2024-02-15 JP JP2024021416A patent/JP2024056905A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016529246A (ja) | 2013-08-06 | 2016-09-23 | オンコエシックス ゲーエムベーハー | Betブロモドメイン阻害剤を用いるびまん性大細胞型b細胞性リンパ腫(dlbcl)の治療方法 |
WO2015058160A1 (en) | 2013-10-18 | 2015-04-23 | Quanticel Pharmaceuticals, Inc. | Bromodomain inhibitors |
WO2015078929A1 (en) | 2013-11-27 | 2015-06-04 | Oncoethix Sa | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds |
Non-Patent Citations (2)
Title |
---|
森部久仁一、山本恵司,非晶質医薬品の調製と評価,低温生物工学会誌,2005年,Vol.51, No.1,p.19-24 |
難水溶性薬物の経口製剤化技術最前線,株式会社シーエムシー出版,2016年07月,p.64,127-135 |
Also Published As
Publication number | Publication date |
---|---|
JP2022095897A (ja) | 2022-06-28 |
AU2017345468A1 (en) | 2019-06-06 |
AU2017345468B2 (en) | 2022-06-02 |
WO2018075796A1 (en) | 2018-04-26 |
JP2019535671A (ja) | 2019-12-12 |
AR109859A1 (es) | 2019-01-30 |
CN110099685A (zh) | 2019-08-06 |
EP3528810A4 (en) | 2020-06-17 |
TW201821062A (zh) | 2018-06-16 |
EP3528810A1 (en) | 2019-08-28 |
JP2024056905A (ja) | 2024-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2983446C (en) | Bromodomain inhibitor | |
JP2024056905A (ja) | ブロモドメイン阻害剤 | |
CN113226302B (zh) | 用于治疗或预防痛风或高尿酸血症的化合物的晶型 | |
JP2022510303A (ja) | 痛風または高尿酸血症を処置または予防するための方法 | |
CA3140412A1 (en) | Compound for treating gout or hyperuricemia | |
US20230301983A1 (en) | Bromodomain inhibitor | |
WO2023098872A1 (en) | Crystalline forms of a compound for treating or preventing gout or hyperuricemia | |
JP7397487B2 (ja) | 感覚有毛細胞死を予防または処置するための化合物の結晶形態 | |
CN112438978B (zh) | 一种西达本胺药物组合物及其制备方法和应用 | |
EA043666B1 (ru) | Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200914 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200914 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210630 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211012 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220414 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220414 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20220415 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220418 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20220517 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220622 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220628 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220726 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220823 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7129973 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |